• Users Online: 858
  • Print this page
  • Email this page
 
CASE REPORT
Ahead of Print

Application of color doppler ultrasound to evaluate chemotherapeutic effect on primary thyroid lymphoma


1 Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan
2 Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defence Medical Center, Taipei City, Taiwan

Correspondence Address:
Cheng-Chuan Hu,
Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei City
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Primary thyroid lymphoma (PTL) is a rare disease which responds well to rituximab-based chemotherapy. Here, we describe a case who was diagnosed through core needle biopsy as having diffuse large B-cell lymphoma in the right lobe of thyroid gland. Positron emission tomography computed tomography (PET-CT) revealed no other foci of hot spots, so PTL was considered. She was treated with rituximab plus bendamustine for three cycles, and color Doppler ultrasound revealed significant reduction of blood flow signals in the tumor but no significant decrease of its size (<25% extent). Then, the chemotherapy regimen was adjusted to rituximab, cyclophosphamide, vincristine, prednisone (R–COP), and complete remission was noted on ultrasound and PET-CT after three cycles of R–COP treatment. This case is reported to tell that color Doppler ultrasound, in addition to PET-CT, is useful to evaluate chemotherapeutic effect on PTLs.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Hu CC
    -  Wang CW
    -  Chen JH
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed552    
    PDF Downloaded21    

Recommend this journal